|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US7419964B2
(en)
*
|
1999-09-16 |
2008-09-02 |
Cytogenix, Inc. |
Treatment of HSV-related pathologies using ssDNA
|
|
AU7855300A
(en)
*
|
1999-10-04 |
2001-05-10 |
Cytogenix, Inc. |
Altering gene expression with ssDNA produced in vivo
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
AU2001277194A1
(en)
*
|
2000-07-28 |
2002-02-13 |
Oligotrail, Llc. |
Transgenic identification markers
|
|
US7312325B2
(en)
|
2000-09-26 |
2007-12-25 |
Duke University |
RNA aptamers and methods for identifying the same
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7300922B2
(en)
|
2001-05-25 |
2007-11-27 |
Duke University |
Modulators of pharmacological agents
|
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
|
EP1468086A2
(en)
*
|
2001-12-14 |
2004-10-20 |
Yale University |
INTRACELLULAR GENERATION OF SINGLE−STRANDED DNA
|
|
WO2003093424A2
(en)
*
|
2002-05-01 |
2003-11-13 |
Cytogenix, Inc. |
In vivo ssdna expression vectors for altering gene expression
|
|
US20050020526A1
(en)
*
|
2003-06-03 |
2005-01-27 |
Cytogenix, Inc. |
Oligodeoxynucleotide intervention for prevention and treatment of sepsis
|
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
|
PL1745062T3
(pl)
|
2004-04-22 |
2014-10-31 |
Regado Biosciences Inc |
Ulepszone modulatory czynników krzepnięcia
|
|
AU2005290337A1
(en)
*
|
2004-09-28 |
2006-04-06 |
Cytogenix, Inc. |
Single-stranded antimicrobial oligonucleotides and uses thereof
|
|
CA2626690A1
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
|
US8658608B2
(en)
|
2005-11-23 |
2014-02-25 |
Yale University |
Modified triple-helix forming oligonucleotides for targeted mutagenesis
|
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
|
ES2874149T3
(es)
|
2006-05-11 |
2021-11-04 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen PCSK9
|
|
EP2392583A1
(en)
|
2006-05-19 |
2011-12-07 |
Alnylam Europe AG. |
RNAi modulation of Aha and therapeutic uses thereof
|
|
EP2584051B1
(en)
|
2006-05-22 |
2014-07-16 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expressions of IKK-B gene
|
|
AU2007297388A1
(en)
|
2006-09-18 |
2008-03-27 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of scap and therapeutic uses thereof
|
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
|
ES2428009T3
(es)
|
2007-07-05 |
2013-11-05 |
Novartis Ag |
ARNds para tratar infecciones virales
|
|
EP2848688A1
(en)
|
2007-12-10 |
2015-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
|
SG188121A1
(en)
|
2008-03-05 |
2013-03-28 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
EP3208337A1
(en)
|
2008-09-02 |
2017-08-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions for combined inhibition of mutant egfr and il-6 expression
|
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
EA036772B1
(ru)
|
2008-10-20 |
2020-12-18 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
|
EP2373382B1
(en)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
EP3329924B1
(en)
|
2010-03-29 |
2021-05-05 |
Alnylam Pharmaceuticals, Inc. |
Dsrna therapy for transthyretin (ttr) related ocular amyloidosis
|
|
CA2792561C
(en)
|
2010-04-06 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for increasing erythropoietin (epo) production
|
|
KR102365961B1
(ko)
|
2011-03-29 |
2022-02-23 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
EP2723861A4
(en)
|
2011-06-21 |
2014-12-10 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
|
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
ES2923573T3
(es)
|
2011-06-21 |
2022-09-28 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
|
|
CN103649103A
(zh)
|
2011-06-21 |
2014-03-19 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
|
EP3366312A1
(en)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Serpina 1 sirnas: compositions of matter and methods of treatment
|
|
JP2014526887A
(ja)
|
2011-08-01 |
2014-10-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
造血幹細胞移植の成功率を改善する方法
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
US10125369B2
(en)
|
2012-12-05 |
2018-11-13 |
Alnylam Pharmaceuticals, Inc. |
PCSK9 iRNA compositions and methods of use thereof
|
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
|
KR102127358B1
(ko)
|
2013-03-13 |
2020-06-29 |
지니위브 바이오사이언시스, 인코포레이티드 |
비-복제 형질도입 입자 및 형질도입 입자-기반 리포터 시스템
|
|
CA3216595A1
(en)
|
2013-03-14 |
2014-10-02 |
Kevin Fitzgerald |
Complement component c5 irna compositions and methods of use thereof
|
|
EP2978446B1
(en)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antibody for use in treating alzheimer's disease
|
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
TW201936624A
(zh)
|
2013-05-22 |
2019-09-16 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
KR102486617B1
(ko)
|
2013-05-22 |
2023-01-12 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 조성물 및 이의 사용 방법
|
|
US10077444B2
(en)
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
TWI768330B
(zh)
|
2013-10-04 |
2022-06-21 |
美國西奈山伊坎醫學院 |
抑制alas1基因表現的組合物及方法
|
|
SG10201804960RA
(en)
|
2013-12-12 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
AU2015217301A1
(en)
|
2014-02-11 |
2016-08-25 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
|
CA3215908A1
(en)
|
2014-05-22 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
TWI864340B
(zh)
|
2014-10-10 |
2024-12-01 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
TWI710633B
(zh)
|
2014-11-10 |
2020-11-21 |
美商阿尼拉製藥公司 |
B型肝炎病毒(HBV)iRNA組成物及其用途方法
|
|
HK1244843A1
(zh)
|
2014-11-17 |
2018-08-17 |
Alnylam Pharmaceuticals, Inc. |
载脂蛋白c3(apoc3)irna组合物及其使用方法
|
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
EA201792263A1
(ru)
|
2015-04-13 |
2018-08-31 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
KR102827366B1
(ko)
|
2015-05-06 |
2025-07-03 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 XII(하게만 인자)(F12), 칼리크레인 B, 혈장(플레처 인자) 1(KLKB1) 및 키니노겐 1(KNG1) iRNA 조성물 및 그의 이용 방법
|
|
EP4365291A3
(en)
|
2015-06-12 |
2024-08-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
KR20250145703A
(ko)
|
2015-09-02 |
2025-10-13 |
알닐람 파마슈티칼스 인코포레이티드 |
프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
|
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
|
FI3386518T3
(fi)
|
2015-12-07 |
2025-09-25 |
Genzyme Corp |
Menetelmiä ja koostumuksia serpinc1:een liittyvän häiriön hoitamiseksi
|
|
WO2017100542A1
(en)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
|
|
US11136597B2
(en)
|
2016-02-16 |
2021-10-05 |
Yale University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
AU2017376950B2
(en)
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
|
IL269927B2
(en)
|
2017-04-18 |
2025-04-01 |
Alnylam Pharmaceuticals Inc |
Methods of treating patients with hepatitis B virus infection
|
|
UY37803A
(es)
|
2017-07-10 |
2019-02-28 |
Genzyme Corp |
Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia
|
|
AU2018301477A1
(en)
|
2017-07-13 |
2020-02-27 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
|
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
JP2021508491A
(ja)
|
2017-12-18 |
2021-03-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
高移動度グループボックス−1(HMGB1)iRNA組成物及びその使用方法
|
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
CA3105385A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
EP3884051A2
(en)
|
2018-11-23 |
2021-09-29 |
Sanofi |
Novel rna compositions and methods for inhibiting angptl8
|
|
WO2020136154A1
(en)
|
2018-12-27 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Non-replicative transduction particles and transduction particle-based reporter systems for detection of acinetobacter baumannii
|
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
|
AU2020343255A1
(en)
|
2019-09-03 |
2022-03-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
GB201913898D0
(en)
*
|
2019-09-26 |
2019-11-13 |
Lightbio Ltd |
Nucleic acid construct
|
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
EP4041308A1
(en)
|
2019-10-07 |
2022-08-17 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
TW202134435A
(zh)
|
2019-10-22 |
2021-09-16 |
美商阿尼拉製藥公司 |
補體成分c3 irna組成物及其使用方法
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CN119499394A
(zh)
|
2019-11-01 |
2025-02-25 |
阿尔尼拉姆医药品有限公司 |
亨廷顿(HTT)iRNA药剂组合物及其使用方法
|
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
EP4073251A1
(en)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
|
|
US20220356537A1
(en)
|
2019-12-31 |
2022-11-10 |
Roche Molecular Systems, Inc. |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
MX2022009763A
(es)
|
2020-02-10 |
2022-09-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
|
|
KR20220143106A
(ko)
|
2020-02-18 |
2022-10-24 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
|
|
BR112022017822A2
(pt)
|
2020-03-06 |
2022-11-08 |
Alnylam Pharmaceuticals Inc |
Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
|
|
CN116096886A
(zh)
|
2020-03-11 |
2023-05-09 |
欧米茄治疗公司 |
用于调节叉头框p3(foxp3)基因表达的组合物和方法
|
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
WO2021202902A1
(en)
|
2020-04-01 |
2021-10-07 |
Alnylam Pharmaceuticals, Inc. |
ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4133078A1
(en)
|
2020-04-06 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
KR20230018377A
(ko)
|
2020-04-27 |
2023-02-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
|
|
MX2022013606A
(es)
|
2020-04-30 |
2023-01-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
TW202214856A
(zh)
|
2020-06-18 |
2022-04-16 |
美商阿尼拉製藥公司 |
黃嘌呤脫氫酶(XDH)iRNA組成物及其使用之方法
|
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法
|
|
JP2023546103A
(ja)
|
2020-10-16 |
2023-11-01 |
サノフイ |
Angptl3を阻害するための新規のrna組成物および方法
|
|
US20240035029A1
(en)
|
2020-10-16 |
2024-02-01 |
Sanofi |
Rna compositions and methods for inhibiting lipoprotein(a)
|
|
EP4232581A1
(en)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
KR20230107625A
(ko)
|
2020-11-13 |
2023-07-17 |
알닐람 파마슈티칼스 인코포레이티드 |
응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
|
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
|
TW202302847A
(zh)
|
2021-02-26 |
2023-01-16 |
美商艾拉倫製藥股份有限公司 |
己酮糖激酶(KHK)iRNA組成物及其使用方法
|
|
IL305442A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
WO2022212231A2
(en)
|
2021-03-29 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
MX2023012586A
(es)
|
2021-04-26 |
2023-10-31 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de serina 6, proteasa transmembranaria (tmprss6) y sus metodos de uso.
|
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
CN117561334A
(zh)
|
2021-06-04 |
2024-02-13 |
阿尔尼拉姆医药品有限公司 |
人染色体9开放阅读框72(C9ORF72)iRNA药剂组合物和其使用方法
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
IL309296A
(en)
|
2021-06-30 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
|
TW202421169A
(zh)
|
2021-07-21 |
2024-06-01 |
美商艾拉倫製藥股份有限公司 |
代謝疾患相關的標靶基因iRNA組成物及其使用方法
|
|
CA3226878A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
JP2024529437A
(ja)
|
2021-07-29 |
2024-08-06 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
3-ヒドロキシ-3-メチルグリタル-COAレダクターゼ(HMGCR)iRNA組成物およびその使用方法
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
IL310295A
(en)
|
2021-08-04 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
iRNA compositions and methods for silencing angiotensinogen (AGT)
|
|
KR20240045300A
(ko)
|
2021-08-13 |
2024-04-05 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 XII (F12) iRNA 조성물 및 이의 사용 방법
|
|
WO2023034837A2
(en)
|
2021-08-31 |
2023-03-09 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体成分(C3)をサイレンシングするためのiRNA組成物および方法
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
KR20240067943A
(ko)
|
2021-09-24 |
2024-05-17 |
알닐람 파마슈티칼스 인코포레이티드 |
미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
|
|
MX2024004437A
(es)
|
2021-10-15 |
2024-07-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de inhibidor de la angiotensina-receptor neprilisina (arni) de administracion extrahepatica y metodos de uso de las mismas.
|
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子b(cfb)irna組成物及其使用方法
|
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
JP2025532593A
(ja)
|
2022-09-15 |
2025-10-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
17b-ヒドロキシステロイドデヒドロゲナーゼ13型(hsd17b13)irna組成物およびその使用方法
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
KR20260049597A
(ko)
|
2023-08-04 |
2026-04-14 |
알닐람 파마슈티칼스 인코포레이티드 |
Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
|
|
CN117143897B
(zh)
*
|
2023-09-07 |
2025-05-16 |
华东理工大学 |
一种生物发酵法制备稳定同位素标记ssDNA的方法
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
TW202603166A
(zh)
|
2024-03-20 |
2026-01-16 |
美商維泰克斯製藥公司 |
黏蛋白5B(MUC5B)靶向siRNA及反義寡核苷酸及其使用方法
|
|
WO2025259747A2
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
|